CA2903382A1 - Methods and systems for enhanced microfluidic processing - Google Patents
Methods and systems for enhanced microfluidic processing Download PDFInfo
- Publication number
- CA2903382A1 CA2903382A1 CA2903382A CA2903382A CA2903382A1 CA 2903382 A1 CA2903382 A1 CA 2903382A1 CA 2903382 A CA2903382 A CA 2903382A CA 2903382 A CA2903382 A CA 2903382A CA 2903382 A1 CA2903382 A1 CA 2903382A1
- Authority
- CA
- Canada
- Prior art keywords
- cartridge
- fluid
- microfluidic
- molecule
- actuator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 126
- 238000012545 processing Methods 0.000 title claims abstract description 80
- 238000006243 chemical reaction Methods 0.000 claims abstract description 43
- 238000002372 labelling Methods 0.000 claims abstract description 31
- 239000000126 substance Substances 0.000 claims abstract description 26
- 239000012491 analyte Substances 0.000 claims abstract description 25
- 238000004458 analytical method Methods 0.000 claims abstract description 12
- 239000011521 glass Substances 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims description 385
- 239000000523 sample Substances 0.000 claims description 90
- 239000000243 solution Substances 0.000 claims description 78
- 239000011324 bead Substances 0.000 claims description 70
- 239000003153 chemical reaction reagent Substances 0.000 claims description 60
- 150000007523 nucleic acids Chemical class 0.000 claims description 59
- 108020004707 nucleic acids Proteins 0.000 claims description 47
- 102000039446 nucleic acids Human genes 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000007858 starting material Substances 0.000 claims description 34
- 230000003321 amplification Effects 0.000 claims description 33
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 33
- 230000008569 process Effects 0.000 claims description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
- 238000003556 assay Methods 0.000 claims description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 30
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- 229940088598 enzyme Drugs 0.000 claims description 29
- 238000005370 electroosmosis Methods 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 27
- 108020004414 DNA Proteins 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 23
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 20
- 239000002751 oligonucleotide probe Substances 0.000 claims description 20
- 238000003752 polymerase chain reaction Methods 0.000 claims description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims description 19
- 241000894007 species Species 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 18
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 17
- 238000010248 power generation Methods 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 16
- 239000003599 detergent Substances 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 15
- 239000000377 silicon dioxide Substances 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 239000012620 biological material Substances 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 11
- 230000002934 lysing effect Effects 0.000 claims description 11
- 230000007246 mechanism Effects 0.000 claims description 11
- 239000003504 photosensitizing agent Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 108091093088 Amplicon Proteins 0.000 claims description 9
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 229920002527 Glycogen Polymers 0.000 claims description 8
- 229940096919 glycogen Drugs 0.000 claims description 8
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 8
- 150000002602 lanthanoids Chemical class 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 230000005298 paramagnetic effect Effects 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 239000011343 solid material Substances 0.000 claims description 7
- 238000001327 Förster resonance energy transfer Methods 0.000 claims description 6
- 108010014251 Muramidase Proteins 0.000 claims description 6
- 102000016943 Muramidase Human genes 0.000 claims description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000005670 electromagnetic radiation Effects 0.000 claims description 6
- 230000007613 environmental effect Effects 0.000 claims description 6
- 229960000274 lysozyme Drugs 0.000 claims description 6
- 239000004325 lysozyme Substances 0.000 claims description 6
- 235000010335 lysozyme Nutrition 0.000 claims description 6
- 239000004065 semiconductor Substances 0.000 claims description 6
- 239000002689 soil Substances 0.000 claims description 6
- 102100034343 Integrase Human genes 0.000 claims description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 230000000704 physical effect Effects 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000002096 quantum dot Substances 0.000 claims description 5
- 238000002165 resonance energy transfer Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 238000005481 NMR spectroscopy Methods 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 239000003637 basic solution Substances 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 3
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 3
- 102000003844 DNA helicases Human genes 0.000 claims description 3
- 108090000133 DNA helicases Proteins 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 3
- 102000018120 Recombinases Human genes 0.000 claims description 3
- 108010091086 Recombinases Proteins 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 230000003467 diminishing effect Effects 0.000 claims description 3
- 230000005281 excited state Effects 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 210000003463 organelle Anatomy 0.000 claims description 3
- 239000002831 pharmacologic agent Substances 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 3
- 238000012358 sourcing Methods 0.000 claims description 3
- 238000012384 transportation and delivery Methods 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 108700019961 Neoplasm Genes Proteins 0.000 claims description 2
- 102000048850 Neoplasm Genes Human genes 0.000 claims description 2
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 claims description 2
- 239000013536 elastomeric material Substances 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 32
- 239000000376 reactant Substances 0.000 abstract description 27
- 238000001514 detection method Methods 0.000 abstract description 23
- 238000005842 biochemical reaction Methods 0.000 abstract description 6
- 229920003023 plastic Polymers 0.000 abstract description 6
- 239000004033 plastic Substances 0.000 abstract description 6
- 229910052751 metal Inorganic materials 0.000 abstract description 4
- 239000002184 metal Substances 0.000 abstract description 4
- 238000005192 partition Methods 0.000 description 28
- 238000010839 reverse transcription Methods 0.000 description 17
- 230000005284 excitation Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 7
- 230000005684 electric field Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 230000000541 pulsatile effect Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 capillary tube Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 241000725619 Dengue virus Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000004146 energy storage Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000005499 meniscus Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000003466 welding Methods 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 3
- 230000004323 axial length Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000005465 channeling Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 229910052581 Si3N4 Inorganic materials 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000007843 droplet-based assay Methods 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- VQTBINYMFPKLQD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(3-hydroxy-6-oxoxanthen-9-yl)benzoate Chemical compound C=12C=CC(=O)C=C2OC2=CC(O)=CC=C2C=1C1=CC=CC=C1C(=O)ON1C(=O)CCC1=O VQTBINYMFPKLQD-UHFFFAOYSA-N 0.000 description 1
- AYDAHOIUHVUJHQ-UHFFFAOYSA-N 1-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)pyrrole-2,5-dione Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2N1C(=O)C=CC1=O AYDAHOIUHVUJHQ-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101100119134 Homo sapiens ESRRB gene Proteins 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- MGPYJVWEJNTXLC-UHFFFAOYSA-N [6-[6-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxyhexylcarbamoyl]-6'-(2,2-dimethylpropanoyloxy)-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] 2,2-dimethylpropanoate Chemical compound C12=CC=C(OC(=O)C(C)(C)C)C=C2OC2=CC(OC(=O)C(C)(C)C)=CC=C2C11OC(=O)C2=CC=C(C(=O)NCCCCCCOP(N(C(C)C)C(C)C)OCCC#N)C=C21 MGPYJVWEJNTXLC-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 238000007812 electrochemical assay Methods 0.000 description 1
- 230000005288 electromagnetic effect Effects 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010026195 glycanase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000010832 regulated medical waste Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 101150090202 rpoB gene Proteins 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 230000005676 thermoelectric effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/50273—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means or forces applied to move the fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/12—Specific details about materials
- B01L2300/123—Flexible; Elastomeric
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
- B01L2400/0418—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic electro-osmotic flow [EOF]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771708P | 2013-03-01 | 2013-03-01 | |
| US61/771,708 | 2013-03-01 | ||
| PCT/US2014/020029 WO2014137940A1 (en) | 2013-03-01 | 2014-03-03 | Methods and systems for enhanced microfluidic processing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2903382A1 true CA2903382A1 (en) | 2014-09-12 |
Family
ID=51491830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2903382A Abandoned CA2903382A1 (en) | 2013-03-01 | 2014-03-03 | Methods and systems for enhanced microfluidic processing |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2962092A4 (de) |
| JP (2) | JP2016516562A (de) |
| CA (1) | CA2903382A1 (de) |
| WO (1) | WO2014137940A1 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066884A1 (en) * | 2015-10-23 | 2017-04-27 | The Royal Institution For The Advancement Of Learning/Mcgill University | Fluidic circuits and methods for bacterial screening |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105758942B (zh) * | 2014-12-16 | 2019-01-04 | 中国科学院大连化学物理研究所 | 基于多种核酸适体的多蛋白同时在线富集检测方法 |
| CN105241941A (zh) * | 2015-09-06 | 2016-01-13 | 常州大学 | 一种毛细管内快速检测酶浓度的方法 |
| WO2018025899A1 (ja) * | 2016-08-03 | 2018-02-08 | 和光純薬工業株式会社 | プラスチック製マイクロ流体デバイス充填用溶液 |
| JP6759841B2 (ja) * | 2016-08-15 | 2020-09-23 | 住友ゴム工業株式会社 | マイクロ流路チップ |
| US11865540B2 (en) * | 2016-09-23 | 2024-01-09 | Hewlett-Packard Development Company, L.P. | Microfluidic device |
| PL235210B1 (pl) * | 2016-12-21 | 2020-06-15 | Genomtec Spolka Akcyjna | Sposób detekcji materiału genetycznego w próbce biologicznej oraz urządzenie do jego realizacji |
| JP6863074B2 (ja) * | 2017-05-24 | 2021-04-21 | 住友ゴム工業株式会社 | マイクロ流路チップ |
| SG11202002931VA (en) * | 2017-11-09 | 2020-04-29 | Visby Medical Inc | Portable molecular diagnostic device and methods for the detection of target viruses |
| US10046322B1 (en) | 2018-03-22 | 2018-08-14 | Talis Biomedical Corporation | Reaction well for assay device |
| CN109576345A (zh) * | 2018-10-17 | 2019-04-05 | 西人马（厦门）科技有限公司 | 一种用于dna提取的微流控芯片及其检测方法 |
| KR102329337B1 (ko) * | 2020-01-21 | 2021-11-19 | (주)옵토레인 | 푸시타입 pcr용 카트리지 |
| CN116930298B (zh) * | 2023-09-14 | 2023-12-26 | 古镜科技(深圳)有限公司 | 用于检测hiv的电化学生物传感器及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998000231A1 (en) * | 1996-06-28 | 1998-01-08 | Caliper Technologies Corporation | High-throughput screening assay systems in microscale fluidic devices |
| US5800690A (en) | 1996-07-03 | 1998-09-01 | Caliper Technologies Corporation | Variable control of electroosmotic and/or electrophoretic forces within a fluid-containing structure via electrical forces |
| US6391622B1 (en) * | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
| US6416642B1 (en) * | 1999-01-21 | 2002-07-09 | Caliper Technologies Corp. | Method and apparatus for continuous liquid flow in microscale channels using pressure injection, wicking, and electrokinetic injection |
| ATE448875T1 (de) * | 2000-09-14 | 2009-12-15 | Caliper Life Sciences Inc | Mikrofluidische vorrichtungen und methoden um temperatur-vermittelte reaktionen durchzuführen |
| US7214300B2 (en) * | 2001-06-04 | 2007-05-08 | Epocal Inc. | Integrated electrokinetic devices and methods of manufacture |
| US7235164B2 (en) * | 2002-10-18 | 2007-06-26 | Eksigent Technologies, Llc | Electrokinetic pump having capacitive electrodes |
| NL1023404C2 (nl) * | 2003-05-13 | 2004-11-16 | Berkin Bv | Inrichting voor het regelen van het massadebiet van een vloeistofstroom in een vloeistofkanaal. |
| US7316543B2 (en) * | 2003-05-30 | 2008-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Electroosmotic micropump with planar features |
| US20050034990A1 (en) * | 2003-08-12 | 2005-02-17 | Crooks Richard M. | System and method for electrokinetic trapping and concentration enrichment of analytes in a microfluidic channel |
| JP4593373B2 (ja) * | 2004-06-07 | 2010-12-08 | ナノフュージョン株式会社 | 電気浸透流ポンプシステム及び電気浸透流ポンプ |
| US9535056B2 (en) * | 2008-01-10 | 2017-01-03 | L'oreal | Immune system modeling devices and methods |
| EP2346604A1 (de) * | 2008-11-13 | 2011-07-27 | Koninklijke Philips Electronics N.V. | Koppeln eines einlasses an einen kapillarkanal eines mikrofluidsystems |
| CN102239409A (zh) * | 2008-12-05 | 2011-11-09 | 纳诺维德公司 | 用于及时护理分析仪的基于微流的实验室测试卡 |
| EP3415235A1 (de) * | 2009-03-23 | 2018-12-19 | Raindance Technologies Inc. | Manipulation von mikrofluidiktröpfchen |
| AU2010249678B2 (en) * | 2009-05-19 | 2014-08-28 | The Regents Of The University Of California | Multi-directional microfluidic devices and methods |
| SE534488C2 (sv) * | 2010-02-22 | 2011-09-06 | Lunavation Ab | Ett system för elektrokinetisk flödesteknik |
| JP2012251927A (ja) * | 2011-06-06 | 2012-12-20 | National Institute Of Advanced Industrial & Technology | 標的物質検出用マイクロチップ |
-
2014
- 2014-03-03 WO PCT/US2014/020029 patent/WO2014137940A1/en active Application Filing
- 2014-03-03 CA CA2903382A patent/CA2903382A1/en not_active Abandoned
- 2014-03-03 JP JP2015560397A patent/JP2016516562A/ja active Pending
- 2014-03-03 EP EP14761250.1A patent/EP2962092A4/de not_active Withdrawn
-
2019
- 2019-03-28 JP JP2019063904A patent/JP2019162623A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066884A1 (en) * | 2015-10-23 | 2017-04-27 | The Royal Institution For The Advancement Of Learning/Mcgill University | Fluidic circuits and methods for bacterial screening |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2962092A4 (de) | 2016-08-24 |
| WO2014137940A1 (en) | 2014-09-12 |
| JP2016516562A (ja) | 2016-06-09 |
| JP2019162623A (ja) | 2019-09-26 |
| EP2962092A1 (de) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10955067B2 (en) | Methods and systems for enhanced microfluidic processing | |
| CA2903382A1 (en) | Methods and systems for enhanced microfluidic processing | |
| CN101990516B (zh) | 多用试样准备系统及其在集成分析系统中的使用 | |
| Bousse et al. | Electrokinetically controlled microfluidic analysis systems | |
| US6524790B1 (en) | Apparatus and methods for correcting for variable velocity in microfluidic systems | |
| EP1317569B1 (de) | MIKROFLUIDISCHE VORRICHTUNGEN UND METHODEN UM TEMPERATUR-VERMITTELTE REAKTIONEN DURCHZUFüHREN | |
| US20120028311A1 (en) | Cartridge with lysis chamber and droplet generator | |
| KR20080096567A (ko) | 마이크로유체 장치 | |
| US11607689B2 (en) | Systems and methods related to continuous flow droplet reaction | |
| KR20070063542A (ko) | 미세유동 장치 | |
| MXPA05004606A (es) | Sistema microfluidico apara analisis de acidos nucleicos. | |
| EP3366375B1 (de) | Flüssigkeitssendeverfahren mithilfe eines probenverarbeitungschips und flüssigkeitssendevorrichtung für probenverarbeitungschip | |
| JP6796067B2 (ja) | スペーサによって分離された液体体積の配列を処理するためのマイクロ流体プローブ・ヘッド | |
| EP2611541A2 (de) | Verfahren, vorrichtungen und systeme zur mischung von fluiden und chip-schnittstelle dafür | |
| JP2003507737A (ja) | 単一真空源を有する高スループットシステムにおける稀釈 | |
| US11865535B2 (en) | Microfluidic reaction system | |
| JP2006284451A (ja) | 検体中の標的物質を分析するためのマイクロ総合分析システム | |
| Chen et al. | High-throughput droplet analysis and multiplex DNA detection in the microfluidic platform equipped with a robust sample-introduction technique | |
| US20210362151A1 (en) | Methods and devices for mixing in a microfluidic system | |
| JP2020094993A (ja) | カートリッジ及び分析システム |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190228 |
|
| FZDE | Discontinued |
Effective date: 20220110 |
|
| FZDE | Discontinued |
Effective date: 20220110 |